Estonian research will be presented at Europe’s largest interdisciplinary science meeting „EuroScience Open Forum“ July 9-14, 2018 in Toulouse, France. We showcase some of the highlights of Estonian research at the exhibition area through the themes of smart living environment, eHealth and cybersecurity, and spread information about research opportunities in Estonia. Also, on the Science to Business session, we will argue that personalized medicine that incorporates the genetic makeup of individuals can drastically improve the health and life expectancy of people in the future.
EuroScience Open Forum is a great arena to come and learn about Estonian research and researcher. We are looking forward to see you and share our knowledge!
More information about the event.
Science-to-Business session / Session Science-Commerce 13/07/18 8:45-10:00
Boulevard Lascrosses, 8 Esplanade Compans-Cafarelli
Hotel Mercure Toulouse Centre Compans
Getting Personal with Personalised Medicine / Aller plus loin avec les soins personnalisés
The session will discuss targeted and personalised approaches to genetic disease risk and drug response assessment. It will highlight from different angles how medical diagnostics and treatment are moving from general population-based figures to personal genetic data. The question is no longer “Will it work?“ but rather “Will it work on him/her “? The answer resides in our genes, our health behavior and the environment where we live. Finally, it will bring the person into the center of healthcare as treatment will be tailored to match the genes and lifestyle.
During the session the experts from the Estonian Ministry of Social Affairs, Estonian Biobank, Illumina Inc. (genetic profiling technology provider), Oxford Nanopore Technologies (biological analysis provider) and Biogen Inc. (multinational biotechnology company) will discuss how implementation of genetic analysis in everyday medical practice can eliminate in coming years the trial-and-error method of developing and prescribing drugs, reduce drug toxicity and provide precise and safe treatment to patients. Furthermore, public-private partnerships will be evaluated as a novel model for developing and implementing innovative products and services in healthcare.
The session will argue that personalized medicine that incorporates the genetic makeup of individuals can drastically improve the health and life expectancy of people in the future. The challenges in this process will also be surveyed, acknowledgning that we still have a long road ahead.
Riina SIKKUT – Minister of Health and Labour of the Republic of Estonia
Karol ESTRADA – BioGen Inc, Head of Statistical and Genetic Epidemiology
Bobby KAURA – Associate Director, Commercial Mkt./Biz. Development, Illumina Inc.
Olivier LUCAS – Head of Market Development for Western Europe, Oxford Nanopore Technologies
Tõnu ESKO – Institute of Genomics, Estonian Biobank Research Center, University of Tartu
Lili MILANI – Estonian Genome Center, University of Tartu
This event is supported by Estonian Research Council through European Union Regional Development Fund.